Pharma BD Deal Intelligence

Repligen Corporation / BioLife Solutions, Inc.

2026 · Acquisition/Merger · $1.5B · Pending

Repligen and BioLife Solutions announced a definitive agreement for Repligen to acquire BioLife for approximately USD 1.5 billion in total enterprise value, comprised of 64 percent Repligen common stock and 36 percent cash. BioLife shareholders receive USD 11.25 in cash plus 0.1442 Repligen shares per BioLife share, equal to USD 31 per share and a 24 percent premium to BioLife's 90-day volume-weighted average price through July 21, 2026. The deal expands Repligen's position in cell and gene therapy bioprocessing through BioLife's CryoStor biopreservation media. Closing is expected in the fourth quarter of 2026, subject to BioLife shareholder approval and regulatory clearances.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals